Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) refer to the most common forms of dementia. Dementia likely affects more than 5 million people in the U.S. and more than 47 million worldwide. Currently, there are no known treatments to prevent or stop the progression of dementia. The toll on individuals, caregivers, and society is enormous and will only increase as the population ages unless effective interventions are developed. NINDS collaborates with NIH's National Institute on Aging (NIA), the lead NIH Institute for Alzheimer's disease (AD) research, to establish research priorities and fund biomedical research in AD as well as several Alzheimer's disease-related dementias (ADRDs).

Treatments for Lewy Body Dementias and Frontotemporal Dementias--Exploratory Clinical Trial (U01) RFA-NS-22-056 This FOA invites applications from investigators seeking to conduct exploratory clinical trials designed to test new treatments for patients with Lewy Body Dementia (LBD) or Frontotemporal Dementia (FTD). **Due Date: November 21, 2022**

Optimization of Genome Editing Therapeutics for ADRD (U01) RFA-NS-23-017 This FOA supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), towards IND-enabling studies. **Due Date: November 30, 2022**

Sleep Disorders and Circadian Clock Disruption in Alzheimer’s Disease and other Dementias of Aging NOT-AG-21-051 This NOSI to supports research to better understand the bi-directional association between sleep disturbances/circadian disruption and Alzheimer's Disease Related Dementias (ADRD). **Expiration: November 13, 2024**

Research on Current Topics in Alzheimer’s Disease and Its Related Dementias (R01) PAR-22-093 This FOA invite applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). **Due dates: March 11, July 8-10, Nov 12-14, 2022-2024**

Administrative Supplements to Promote Diversity for NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Awardees NOT-NS-21-047 This Notice encourages eligible NINDS awardees in the Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) research community to apply for administrative supplements in response to PA-21-07. **Multiple due dates, through March 2024**
NINDS Institutional AD/ADRD Research Training Program (T32) PAR-22-021 This FOA is to provide support for institutional research training programs in Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias (AD/ADRD). **Standard due dates, Expiration: May 26, 2024**

NINDS AD/ADRD Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) PAR-22-022 The purpose of the NINDS AD/ADRD Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research. **Standard due dates, Expiration: July 13, 2024**

**Learn More:**

No RFA is needed to apply!! The NINDS special AD/ADRD payline applies to investigator-initiated research applications to the NIH Parent R01 and to the NINDS R21 (PA-21-219)

Advanced Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44) PAS-22-196 This FOA is to support research that may lead to the development of innovative products and/or services that have the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD. **Standard due dates, Expiration: September 06, 2025**

**Learn More:**

Advanced Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42) PAS-22-197 This FOA is to support research that may lead to the development of innovative products and/or services that have the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD. **Standard due dates, Expiration: September 06, 2025**

Planned Initiative FY2023 Postmortem Neuropathology, Cellular, and Molecular Analyses, Including Ex-Vivo Imaging, to Assess the Significance of Human TBI and VCID AD/ADRD-Relevant Imaging and Clinical Findings During Life